BLSI Boston Life Sciences (MM)

HOPKINTON, Mass., Aug. 30 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI), a biotechnology company focused on diagnostic and therapeutic products for diseases of the Central Nervous System (CNS), today announced that Peter G. Savas, Chairman and CEO, is scheduled to be interviewed this evening on New England Cable News "New England Business Today." The program is scheduled to air at 6:30 PM EDT on local New England cable networks. All "Business Day" interviews are posted on the NECN website, http://www.necn.com/. About New England Business Day Anchors R.D. Sahl, Beth Shelburne and Myriam Wright examine the state of the markets, news of New England businesses and the local economy. Personal finance, investing, consumer news, advertising, mutual funds, the web, high technology, biotechnology, emerging industries, and established New England companies will all be examined in the larger context of the national and international economic landscapes About Boston Life Sciences Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and in Phase II clinical trials for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include INOSINE for the treatment of stroke, a DAT blocker for the treatment of Parkinson's disease and a second generation technetium-based molecular imaging agent for PS and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston. Contact: Sharon Correia -- 508-497-2360 ext 224 Boston Life Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc. CONTACT: Sharon Correia, +1-508-497-2360, ext. 224 of Boston Life Sciences, Inc., Web site: http://www.bostonlifesciences.com/ http://www.necn.com/

Copyright